Accumulation of KRM-1648 by Mycobacterium aurum and Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 5, 2000, Pages 681-684

  Piddock, Laura J V ^a   Ricci, Vito ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; ETHAMBUTOL; POLYSORBATE 80; RESERPINE; RIFALAZIL;

ARTICLE; BACTERICIDAL ACTIVITY; BIOACCUMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; MYCOBACTERIUM AURUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH;

EID: 0034059379     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.5.681     Document Type: Article

References (10)

1. Luna-Herrera, J., Reddy, M. V. & Gangadharam, P. R. (1995). In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy 39, 440-4.
2. Klemens, S. P., Grossi, M. A. & Cynamon, M. H. (1994). Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy 38, 2245-8.
3. Fujii, K., Saito, H., Tomioka, H., Mae, T. & Hosoe, K. (1995). Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrobial Agents and Chemotherapy 39, 1489-92.
4. Moghezeh, S. L., Pan, X., Arain, T., Stover, C. K., Musser, J. M. & Kreiswirth, B. N. (1996). Comparative antimycobacterial activities of rifampicin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrobial Agents and Chemotherapy 40, 2655-7.
5. Mor, N., Simon, B. & Heifets, L. (1996). Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrobial Agents and Chemotherapy 40, 1482-5.
6. Williams, K. J. & Piddock, L. J. (1998). Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 42, 597-603.
7. Piddock, L. J., Williams, K. J. & Ricci, V. (1999). Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy 45, 159-65.
8. Deng, L., Mikusova, K., Robuck, K. G., Scherman, M., Brennan, P. J. & McNeil, M. R. (1995). Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Antimicrobial Agents and Chemotherapy 39, 694-701.
9. Kuze, F., Kurasawa, T., Bando, K., Lee, Y. & Maekawa, N. (1981). In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. Reviews in Infectious Diseases 3, 885-97.
10. Masaki, S., Sugimori, G., Okamoto, A., Imose, J. & Hayashi, Y. (1990). Effect of Tween 80 on the growth of Mycobacterium avium complex. Microbiology and Immunology 34, 653-63.